SPINAL CORD INJURY, INFLAMMATION, AND IMMUNE-DISEASE: LOCAL CONTROLLED RELEASE OF THERAPEUTIC AGENTS

• US 20100196481A1
• Filed: 09/25/2009
• Published: 08/05/2010
• Est. Priority Date: 09/25/2008
• Status: Abandoned Application

• Current Assignee: InVivo Therapeutics Corporation (Invivo Therapeutics Holdings Corp.)
• Original Assignee: InVivo Therapeutics Corporation (Invivo Therapeutics Holdings Corp.)
• Inventors: Woodard, Eric J., Reynolds, Francis M., Pritchard, Christopher D., Langer, Robert S.
• Application Number:
  US12/567,589
• Publication Number:
  US 20100196481A1
• Time in Patent Office: Days
• US Class Current: 424/487
• CPC Class Codes: A61K 31/573 substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• CPC Class Codes: A61K 31/65 Tetracyclines
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 47/32 Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers , poly(meth)acrylates, or polyvinyl pyrrolidone
• CPC Class Codes: A61K 47/34 Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers A61K47/10 takes precedence
• CPC Class Codes: A61K 47/36 Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/0024 Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L
• CPC Class Codes: A61K 9/0085 Brain, e.g. brain implants; Spinal cord
• CPC Class Codes: A61K 9/10 Dispersions; Emulsions A61K9/06 takes precedence; composition of dispersions, emulsions A61K47/00
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/02 for peripheral neuropathies
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 39/06 Free radical scavengers or antioxidants

Abstract

A drug delivery system is provided for treatment of oxidative stress. The drug delivery system can include a therapeutic agent and a matrix. The therapeutic agent can include an antioxidant or steroid. The matrix can include a hydrogel, particle, microparticle, or nanoparticle. A method of treating injury, including peripheral nerve injury or spinal cord injury, is also provided. The method includes injecting the drug delivery system at the site of injury.

Claims

1. A method of treating injury at a site of the injury in a patient comprising administering a drug delivery system having a matrix and one or more therapeutic agents to the patient at the site of injury.

2. The method of claim 1, wherein the step of administering includes injecting the drug delivery system into the patient at the site of the injury.

3. The method of claim 2, wherein the matrix includes a temperature-sensitive hydrogel.

4. The method of claim 3, wherein the temperature-sensitive hydrogel comprises multiblock copolymers where the polymers are selected from one or more of the group consisting of ethylene glycol containing polymers, oligoethylene glycol containing polymers, polyethylene glycol containing polymers, lactide polymers, glycolide polymers, and poly(glycerol-co-sebacic acid).

5. The method of claim 3, wherein the temperature-sensitive hydrogel comprises a combination of polymers having compatible reactive end groups.

6. The method of claim 3, wherein the temperature-sensitive hydrogel comprises thiol esters of thiol containing polymers and acrylate containing polymers.

7. The method of claim 3, wherein the temperature-sensitive hydrogel comprises one or more polymer selected from the group consisting of poly(glycerol-co-sebacic acid) acrylate;

multiblock copolymers of poly(lactide-co-glycolide) and poly(ethylene glycol) or oligo (ethylene glycol) methyl methacrylate;

graft copolymers of poly(glycerol-co-sebacic acid) and poly(ethylene glycol), oligo (ethylene glycol) methyl methacrylate or poly(N-isopropylacrylamide); and

thiol esters of ethoxylated trimethylolpropane tri-3-mercaptopropionate and poly(ethylene glycol) diacrylate.

8. The method of claim 3, wherein the temperature-sensitive hydrogel includes thiol esters of ethoxylated trimethylolpropane tri-3-mercaptopropionate and poly(ethylene glycol) diacrylate.

9. The method of claim 3, wherein the temperature-sensitive hydrogel is biodegradeable and the hydrogel components are biodegradeable or biocompatible and excretable, or the hydrogel includes a mixture of biodegradeable components and biocompatible and excretable components.

10. The method of claim 2, wherein the matrix includes particles.

11. The method of claim 10, wherein the particles are microparticles, nanoparticles, or a combination of microparticles and nanoparticles.

12. The method of claim 10, wherein the particles include a biodegradeable polymer, a biocompatible polymer that is excretable, or a biodegradeable polymer that includes biocompatible and excretable components.

13. The method of claim 10, wherein the particles include a polyester.

14. The method of claim 10, wherein the particles include one or more polymer selected from the group consisting of poly(lactide-co-glycolide);

polylactide, polyglycolide; and

poly(carboxyphenoxy propane)-co-sebacic acid).

15. The method of claim 10, wherein the particles are microparticles including poly(lactide-co-glycolide).

16. The method of claim 2, wherein the one or more therapeutic agents include one or more substance selected from the group consisting of inhibitors of NOS or NO production, antioxidants, spin traps, and peroxynitrite scavengers, or pharmaceutically acceptable salts thereof.

17. The method of claim 2, wherein the one or more therapeutic agents include a substance selected from the group consisting of an antioxidant or antioxidants, tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl), uric acid, minocycline, methylprednisolone, MnTBAP, and dexamethasone, or pharmaceutically acceptable salts thereof.

18. The method of claim 2, wherein the one or more therapeutic agents include methylprednisolone or a pharmaceutically acceptable salt thereof.

19. The method of claim 2, wherein the one or more therapeutic agents include minocycline or a pharmaceutically acceptable salt thereof.

20. The method of claim 2, wherein the one or more therapeutic agents include methylprednisolone and minocycline, or pharmaceutically acceptable salts thereof.

21. The method of claim 2, wherein the matrix is functionalized with the one or more therapeutic agents or pharmaceutically acceptable salts thereof.

22. The method of claim 2, wherein the site of the injury is in the spinal cord and the step of injection includes intradural intrameduallary injection.

23. The method of claim 2, wherein the site of the injury is a peripheral nerve.

24. The method of claim 2, wherein the matrix includes a temperature-sensitive hydrogel and particles.

25. The method of claim 24, wherein the one or more therapeutic agents are dissolved or dispersed in the temperature-sensitive hydrogel, the particles, or both the temperature-sensitive hydrogel and the particles.

26. The method of claim 25, where the one or more therapeutic agents are a plurality of therapeutic agents and one or more of the plurality of therapeutic agents is dissolved or dispersed in the hydrogel and one or more other ones of the plurality of therapeutic agents is dissolved or dispersed in the particles.

27. The method of claim 24, wherein

the temperature-sensitive hydrogel comprises thiol esters of ethoxylated trimethylolpropane tri-3-mercaptopropionate and poly(ethylene glycol) diacrylate, and the particles include microparticles having poly(lactide-co-glycolide);

and

the one or more therapeutic agents includes one or more substance selected from the group consisting of inhibitors of NOS or NO production, antioxidants, spin traps, and peroxynitrite scavengers, or pharmaceutically acceptable salts thereof.

28. The method of claim 27, wherein the one or more therapeutic agents include methylprednisolone or a pharmaceutically acceptable salt thereof.

29. The method of claim 27, wherein the one or more therapeutic agents include minocycline or a pharmaceutically acceptable salt thereof.

30. The method of claim 27, wherein the one or more therapeutic agents include methylprednisolone and minocycline, or pharmaceutically acceptable salts thereof.

31. The method of claim 27, wherein the one or more therapeutic agents are dissolved or dispersed in the microparticle.

32. The method of claim 27, wherein the site of injury is in the spinal cord and the step of injection includes intradural intrameduallary injection.

33. The method of claim 27, wherein the site of injury is a peripheral nerve.

34. The method of claim 27, wherein one or both of the hydrogel and microparticles are functionalized with the one or more therapeutic agent.

35. The method of claim 2, wherein the one or more therapeutic agents include vitamin C and vitamin E.

36. A drug delivery system having a matrix and one or more therapeutic agents.

37. The drug delivery system of claim 36, wherein the matrix includes a temperature-sensitive hydrogel.

38. The drug delivery system of claim 37, wherein the temperature-sensitive hydrogel comprises multiblock copolymers where the polymers are selected from one or more of the group consisting of ethylene glycol containing polymers, oligoethylene glycol containing polymers, polyethylene glycol polymers, lactide polymers, glycolide polymers, and poly(glycerol-co-sebacic acid).

39. The drug delivery system of claim 37, wherein the temperature-sensitive hydrogel comprises a combination of polymers having compatible reactive end groups.

40. The drug delivery system of claim 37, wherein the temperature-sensitive hydrogel comprises thiol esters of thiol containing polymers and acrylate containing polymers.

41. The drug delivery system of claim 37, wherein the temperature-sensitive hydrogel comprises one or more polymer selected from the group consisting of poly(glycerol-co-sebacic acid) acrylate;

multiblock copolymers of poly(lactide-co-glycolide) and poly(ethylene glycol) or oligo (ethylene glycol) methyl methacrylate;

graft copolymers of poly(glycerol-co-sebacic acid) and poly(ethylene glycol), oligo (ethylene glycol) methyl methacrylate or poly(N-isopropylacrylamide); and

thiol esters of ethoxylated trimethylolpropane tri-3-mercaptopropionate and poly(ethylene glycol) diacrylate.

42. The drug delivery system of claim 37, wherein the temperature-sensitive hydrogel includes thiol esters of ethoxylated trimethylolpropane tri-3-mercaptopropionate and poly(ethylene glycol) diacrylate.

43. The drug delivery system of claim 37, wherein the temperature-sensitive hydrogel is biodegradeable and the hydrogel components are biodegradeable or biocompatible and excretable, or the hydrogel includes a mixture of biodegradeable components and biocompatible and excretable components.

44. The drug delivery system of claim 36, wherein the matrix includes particles.

45. The drug delivery system of claim 44, wherein the particles are microparticles, nanoparticles, or a combination of microparticles and nanoparticles.

46. The drug delivery system of claim 44, wherein the particles include a biodegradeable polymer, a biocompatible polymer that is excretable, or a biodegradeable polymer that includes biocompatible and excretable components.

47. The drug delivery system of claim 44, wherein the particles include a polyester.

48. The drug delivery system of claim 44, wherein the particles include one or more polymer selected from the group consisting of poly(lactide-co-glycolide);

polylactide, polyglycolide; and

poly(carboxyphenoxy propane)-co-sebacic acid).

49. The drug delivery system of claim 44, wherein the particles are microparticles including poly(lactide-co-glycolide).

50. The drug delivery system of claim 36, wherein the one or more therapeutic agents include one or more substance selected from the group consisting of inhibitors of NOS or NO production, antioxidants, spin traps, and peroxynitrite scavengers, or pharmaceutically acceptable salts thereof.

51. The drug delivery system of claim 36, wherein the one or more therapeutic agents include a substance selected from the group consisting of an antioxidant or antioxidants, tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl), uric acid, minocycline, methylprednisolone, MnTBAP, and dexamethasone, or pharmaceutically acceptable salts thereof.

52. The drug delivery system of claim 36, wherein the one or more therapeutic agents include methylprednisolone or a pharmaceutically acceptable salt thereof.

53. The drug delivery system of claim 36, wherein the one or more therapeutic agents include minocycline or a pharmaceutically acceptable salt thereof.

54. The drug delivery system of claim 36, wherein the one or more therapeutic agents include methylprednisolone and minocycline, or pharmaceutically acceptable salts thereof.

55. The drug delivery system of claim 36, wherein the matrix is functionalized with the one or more therapeutic agents or pharmaceutically acceptable salts thereof.

56. The drug delivery system of claim 36, wherein the matrix includes a temperature-sensitive hydrogel and particles.

57. The drug delivery system of claim 56, wherein the one or more therapeutic agenta are dissolved or dispersed in the temperature-sensitive hydrogel, the particles, or both the temperature-sensitive hydrogel and the particles.

58. The drug delivery system of claim 57, where the one or more therapeutic agents are a plurality of therapeutic agents and one or more of the plurality of therapeutic agents is dissolved or dispersed in the hydrogel and one or more other ones of the plurality of therapeutic agents is dissolved or dispersed in the particles.

59. The drug delivery system of claim 56, wherein

the hydrogel comprises thiol esters of ethoxylated trimethylolpropane tri-3-mercaptopropionate and poly(ethylene glycol) diacrylate, and the particles include microparticles having poly(lactide-co-glycolide);

and

the one or more therapeutic agents include one or more substance selected from the group consisting of inhibitors of NOS or NO production, antioxidants, spin traps, and peroxynitrite scavengers, or pharmaceutically acceptable salts thereof.

60. The drug delivery system of claim 59, wherein the one or more therapeutic agents include methylprednisolone or a pharmaceutically acceptable salt thereof.

61. The drug delivery system of claim 59, wherein the one or more therapeutic agents include minocycline or a pharmaceutically acceptable salt thereof.

62. The drug delivery system of claim 59, wherein the one or more therapeutic agents include methylprednisolone and minocycline, or pharmaceutically acceptable salts thereof.

63. The drug delivery system of claim 59, wherein the one or more therapeutic agents are dissolved or dispersed in the microparticle.

64. The drug delivery system of claim 36, wherein one or both of the hydrogel and microparticles are functionalized with the one or more therapeutic agent.

65. The drug delivery system of claim 36, wherein the one or more therapeutic agents include vitamin C and vitamin E.